188 related articles for article (PubMed ID: 20981590)
1. [SRC kinases in tumor therapy].
Dempke W; Zippel R
Med Klin (Munich); 2010 Oct; 105(10):711-5. PubMed ID: 20981590
[TBL] [Abstract][Full Text] [Related]
2. The role of Src in solid tumors.
Wheeler DL; Iida M; Dunn EF
Oncologist; 2009 Jul; 14(7):667-78. PubMed ID: 19581523
[TBL] [Abstract][Full Text] [Related]
3. Current status of SRC inhibitors in solid tumor malignancies.
Puls LN; Eadens M; Messersmith W
Oncologist; 2011; 16(5):566-78. PubMed ID: 21521831
[TBL] [Abstract][Full Text] [Related]
4. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Schenone S; Brullo C; Musumeci F; Botta M
Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
[TBL] [Abstract][Full Text] [Related]
5. Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
Homsi J; Cubitt CL; Zhang S; Munster PN; Yu H; Sullivan DM; Jove R; Messina JL; Daud AI
Melanoma Res; 2009 Jun; 19(3):167-75. PubMed ID: 19434004
[TBL] [Abstract][Full Text] [Related]
6. The role of Src in prostate cancer.
Fizazi K
Ann Oncol; 2007 Nov; 18(11):1765-73. PubMed ID: 17426060
[TBL] [Abstract][Full Text] [Related]
7. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
[TBL] [Abstract][Full Text] [Related]
8. An update on dual Src/Abl inhibitors.
Musumeci F; Schenone S; Brullo C; Botta M
Future Med Chem; 2012 Apr; 4(6):799-822. PubMed ID: 22530642
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
Lee D; Gautschi O
Clin Lung Cancer; 2006 May; 7(6):381-4. PubMed ID: 16800962
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib: an anti-tumour agent via Src inhibition.
Gnoni A; Marech I; Silvestris N; Vacca A; Lorusso V
Curr Drug Targets; 2011 Apr; 12(4):563-78. PubMed ID: 21226671
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
Montero JC; Seoane S; Ocaña A; Pandiella A
Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
[TBL] [Abstract][Full Text] [Related]
12. Src as a therapeutic target in men with prostate cancer and bone metastases.
Saad F
BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib in solid tumors.
Kim LC; Rix U; Haura EB
Expert Opin Investig Drugs; 2010 Mar; 19(3):415-25. PubMed ID: 20113198
[TBL] [Abstract][Full Text] [Related]
14. Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.
Ahluwalia MS; de Groot J; Liu WM; Gladson CL
Cancer Lett; 2010 Dec; 298(2):139-49. PubMed ID: 20947248
[TBL] [Abstract][Full Text] [Related]
15. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Johnson FM; Saigal B; Tran H; Donato NJ
Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
[TBL] [Abstract][Full Text] [Related]
16. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
[TBL] [Abstract][Full Text] [Related]
17. Src kinases as therapeutic targets for cancer.
Kim LC; Song L; Haura EB
Nat Rev Clin Oncol; 2009 Oct; 6(10):587-95. PubMed ID: 19787002
[TBL] [Abstract][Full Text] [Related]
18. [Bone targeted therapies: new agents].
Barth C; Massard C; Vignot S
Bull Cancer; 2013 Nov; 100(11):1215-21. PubMed ID: 24158596
[TBL] [Abstract][Full Text] [Related]
19. Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients.
Roseweir AK; Qayyum T; Lim Z; Hammond R; MacDonald AI; Fraser S; Oades GM; Aitchison M; Jones RJ; Edwards J
BMC Cancer; 2016 Mar; 16():229. PubMed ID: 26984511
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.
Wheeler DL; Iida M; Kruser TJ; Nechrebecki MM; Dunn EF; Armstrong EA; Huang S; Harari PM
Cancer Biol Ther; 2009 Apr; 8(8):696-703. PubMed ID: 19276677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
